TARE IN INDIA: CENTRES,
Y-90 ACCESS, AND COSTS
A guide to accessing Y-90 radioembolization in India โ where it is available, what it costs, how it compares to China and Western markets, and how CancerFax coordinates access for international patients.
analyticsAt a Glance
- check_circleIndia's leading cancer centres in Mumbai, Delhi, and Chennai now offer TheraSphere and SIR-Spheres
- check_circleTARE in India costs 40โ60% less than equivalent treatment in the USA or UK
- check_circleJCI and NABH-accredited centres with English-speaking teams and established international patient infrastructure
- check_circleCancerFax coordinates access, eligibility review, and logistics for international patients seeking TARE in India
India's Y-90 Radioembolization Programme โ Overview
India's Y-90 radioembolization programme has grown significantly over the past decade, with several major tertiary cancer centres now offering TheraSphere and SIR-Spheres with partition model dosimetry. India's combination of internationally accredited hospitals, fellowship-trained interventional radiologists, English-language infrastructure, and substantially lower costs than Western markets makes it an increasingly attractive option for international patients.
โFor patients who cannot access TARE in their home country or who are priced out of Western Y-90 programmes, India's established centres offer a credible, quality-assured alternative.โ
Regulatory Environment
Both TheraSphere and SIR-Spheres are approved by India's CDSCO (Central Drugs Standard Control Organisation) for use at authorised nuclear medicine and interventional radiology centres. Y-90 supply is managed through the manufacturers' authorised distributors, with quality-controlled activity shipment to approved treating centres.
Hospital Accreditation
The leading Indian TARE centres hold NABH (National Accreditation Board for Hospitals) and in some cases JCI (Joint Commission International) accreditation โ providing quality and patient safety assurance at internationally recognised standards.
Leading Indian Centres for Y-90 Radioembolization
A reference overview of the major Indian centres where TheraSphere and/or SIR-Spheres Y-90 radioembolization is available for liver cancer patients.
| Centre | City | Accreditation | Y-90 Platform | Notes |
|---|---|---|---|---|
| Tata Memorial Hospital | Mumbai | NABH | TheraSphere / SIR-Spheres | India's premier cancer centre; established liver tumour programme |
| Asian Institute of Gastroenterology (AIG) | Hyderabad | NABH | SIR-Spheres | High-volume GI and hepatobiliary centre with active Y-90 programme |
| Kokilaben Dhirubhai Ambani Hospital | Mumbai | NABH / JCI | TheraSphere | Advanced interventional radiology with nuclear medicine integration |
| Medanta โ The Medicity | Gurugram (Delhi NCR) | JCI / NABH | TheraSphere / SIR-Spheres | North India's largest multi-specialty; established international patient programme |
| Apollo Hospitals (Chennai / Hyderabad) | Chennai / Hyderabad | JCI / NABH | SIR-Spheres | Network hospitals with IR and nuclear medicine capability |
| Manipal Hospital (Bangalore) | Bangalore | NABH | SIR-Spheres | Growing Y-90 programme; strong HCC surgical support |
TARE in India vs TARE in China โ Key Differences
Both countries offer quality Y-90 radioembolization at substantially lower cost than Western markets โ but there are important differences in clinical experience and logistics.
TARE in India
- English as primary clinical languageIndian hospitals operate primarily in English โ no translation is needed for medical records, clinical discussions, or discharge documents.
- Easier access for South Asian, Middle East, and African patientsGeographic proximity, cultural familiarity, and direct flight connections make India the more practical destination for patients from these regions.
- Strong hepatobiliary surgical backupTata Memorial, AIG, Kokilaben, and Medanta all have world-class hepatobiliary surgical teams for patients who may convert from locoregional TARE to resection.
- Lower case volume than China for PVTT-specific TAREIndia's TARE HCC case volume is lower than China's โ particularly for complex PVTT and post-TACE-refractory cases, where Chinese centre experience is deeper.
TARE in China
- World's highest HCC TARE case volumeChinese centres โ particularly EHBH and Zhongshan โ have treated more TARE HCC cases in more diverse clinical contexts than any Indian centres.
- Deepest PVTT-specific TARE experienceChina's PVTT HCC experience is unmatched globally โ for complex Vp3โVp4 cases, Chinese centres are the preferred destination.
- More active clinical trial accessChina hosts more active TARE combination trials (TARE + IO, TARE + targeted therapy) than India โ relevant for patients seeking trial access alongside TARE.
- Language barrier for non-English records from Chinese centresChinese discharge summaries require translation โ managed by CancerFax but an additional step not needed for Indian centres.
TARE in India โ Key Numbers
Practical reference figures for international patients considering Y-90 radioembolization in India.
- USD 8,000โ18,000Approximate TARE cost per session in IndiaCompared to USD 20,000โ35,000+ in the USA or UK โ and broadly comparable to Chinese centre pricing for equivalent-quality programmes.
- 6โ8 centresActive Y-90 centres in India (CDSCO authorised)India's Y-90 programme continues to expand โ the number of authorised centres is growing, with new programmes coming online each year.
- 3โ5 daysTypical mapping-to-treatment interval at Indian centresSlightly shorter than Chinese centres in some cases โ Y-90 activity ordering and logistics in India can be faster for standard doses.
More from the TARE / Y-90 Resource Library
Explore the complete TARE cost comparison and the final guides in the resource library.
Frequently Asked Questions: TARE in India
Are TheraSphere and SIR-Spheres the same quality in India as in the USA?
Yes. TheraSphere and SIR-Spheres are manufactured by the same global manufacturers (Boston Scientific and Sirtex Medical respectively) and shipped to authorised Indian centres through controlled supply chains with the same quality specifications as product shipped to USA or European centres. The radioactive microspheres are identical โ what differs is the institutional expertise and dosimetric protocol applied in their use. CancerFax verifies that the recommended Indian centre uses partition model dosimetry rather than simpler empirical methods before coordinating treatment.
Which Indian city is best for TARE โ Mumbai, Delhi, or Hyderabad?
The best Indian city for TARE depends on: your country of origin (flight connections), your specific tumour type and complexity, and current centre capacity. For most patients: Mumbai (Tata Memorial, Kokilaben) offers the deepest oncology expertise and the most established TARE programme. Delhi NCR (Medanta) is best for patients from Pakistan, Afghanistan, Central Asia, and the Gulf who fly into Delhi. Hyderabad (AIG) has a strong GI oncology programme and is well-connected to Southeast Asia. CancerFax assesses all three cities based on your specific case and availability before recommending a centre.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is TARE in India the Right Option for Your Liver Cancer?
CancerFax reviews your liver tumour records and identifies whether TARE at an Indian specialist centre is the most appropriate and cost-effective option for your case โ coordinating the full access process.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and interventional radiologist before making treatment decisions.